口服霍乱疫苗分次剂量加强接种诱导与全剂量相当的疫苗特异性抗体亲和力:一项随机临床试验
瑞典成人(n=44)完成两剂Dukoral®基础免疫后4个月,随机接受全剂量(n=14)、1/5剂量(n=17)或1/25剂量(n=13)加强接种。1/5和1/25剂量在黏膜和血清中诱导的抗CTB抗体亲和力与全剂量相似,均显著高于基础免疫后;1/5剂量组ALS和血清IgA应答幅度呈非显著降低趋势,1/25剂量组显著降低。
要点
- 基础免疫后4个月,1/5和1/25剂量加强接种诱导的抗CTB抗体亲和力与全剂量相当。
- 1/5剂量组黏膜和血清IgA应答幅度较全剂量呈非显著降低趋势。
- 1/25剂量组黏膜和血清IgA应答幅度显著低于全剂量。
核心结论
- 基础免疫后4个月,Dukoral®分次剂量加强接种可诱导抗类毒素黏膜抗体应答,其抗体亲和力较基础免疫后升高。
研究设计与样本
- 随机、开放标签、探索性II期试验,瑞典成人n=44,完成两剂Dukoral®基础免疫后随机分为三组,4个月后加强接种全剂量(n=14)、1/5剂量(n=17)或1/25剂量(n=13)。
主要发现
- 1/5和1/25加强剂量在ALS和血清样本中诱导显著高于基础免疫后的抗CTB抗体亲和力应答,能力与全剂量相似。
- 1/5加强剂量组ALS和血清IgA应答幅度较全剂量组呈非显著降低趋势。
- 1/25加强剂量组ALS和血清IgA应答幅度显著低于全剂量组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody avidity is an important measure of the quality of vaccine-induced immune responses. Murine and human studies suggest that antibody avidity may be augmented by limiting access to antigen. The primary objective of this study was to evaluate in primed Swedish adults if booster vaccination with fractional doses (1/5th and 1/25th) of a model oral vaccine, the cholera vaccine Dukoral®, results in higher avidity antibody responses compared to boosting with a full vaccine dose. We also evaluated if fractional booster vaccination elicited similar magnitudes of antibody response compared to a full dose, and if the previously observed increase in antibody avidity after booster vaccination 1-2 years later occurred when boosting after a shorter interval. To this end, a randomised, open-label, exploratory Phase-II trial was performed. Swedish adults (n = 44), primed with two full doses of Dukoral®, were randomised into three groups and given a booster dose at either full (n = 14), 1/5th (n = 17) or 1/25th (n = 13) dose four months later. Antibody responses to cholera toxin B-subunit (CTB) were measured in serum and mucosal antibody in lymphocyte secretions (ALS). We found that the 1/5th and 1/25th booster doses had similar abilities as the full dose to induce significantly higher avidity anti-CTB antibody responses in both ALS and serum samples, as compared to after priming vaccination. There was a non-significant trend to lower magnitudes of ALS and serum IgA responses after the 1/5th compared to the full booster dose, and responses after the 1/25th dose were significantly lower. Our findings suggest fractional booster doses of Dukoral® four months after priming result in anti-toxoid mucosal antibody responses with increased antibody avidity compared to after priming vaccinations. ISRCTN registry identifier 11806026.
引用
- Mottram L, Lundgren A, Svennerholm AM, et al. Booster vaccination with a fractional dose of an oral cholera vaccine induces comparable vaccine-specific antibody avidity as a full dose: A randomised clinical trial. Vaccine. 2019. PMID: 31703936. doi:10.1016/j.vaccine.2019.10.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。